Emprocell Clinical Research Private Limited, a active private limited company, was established on 24 April 2006 in Navi Mumbai, Maharashtra, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U24231MH2006PTC161334. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹5.00 Cr and a paid-up capital of ₹4.61 Cr.
Formerly known as Em Pro Cell Research Private Limited. It upholds a active non-compliant status. Employing 5 professional, Its leadership includes Vasily Babiy (Director), Svetlana Babiy (Director), Viktor Radchenko (Director). Past directors included Pranav Anam Harish, Vyankatesh Jethmal Pidiyar, Olga Skrynnyk. Its latest AGM occurred on 31 December 2020, with the balance sheet filed on 31 March 2020. It is based at C-7/1A Ttc Industrial Area, Midc, Village Pawan, E, Navi Mumbai, Maharashtra, 400705.
U24231MH2006PTC161334
161334
24 April 2006
₹5.00 Cr
₹4.61 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Emprocell Clinical Research Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vasily Babiy | Director | 19 Aug 2012 | Current |
| Svetlana Babiy | Director | 09 May 2006 | Current |
| Viktor Radchenko | Director | 10 Jun 2006 | Current |
| Volodymyr Radchenko | Director | 31 Mar 2014 | Current |
| Vladimir Evstakhievich Babiy | Director | 09 May 2006 | Current |
| Elena Babiy | Director | 09 May 2006 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Alternate Director | 21 Feb 2014 | Past |
| Pramod Abcsdd | Director | 15 Apr 2021 | Past |
| Pramod Abcsdd | Director | 19 Aug 2012 | Past |
| Pramod Abcsdd | Additional Director | 22 Nov 2012 | Past |
| Pramod Abcsdd | Additional Director | 22 Nov 2012 | Past |
| Pramod Abcsdd | Additional Director | 16 Dec 2014 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Emprocell Clinical Research Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 51.5% decrease. The company also saw a substantial improvement in profitability, with a 14.89% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.59%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2020, Emprocell Clinical Research had a promoter holding of 95.52% and a public holding of 4.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Emprocell Clinical Research has a workforce of 5 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Emprocell Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emprocell Clinical Research's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Emprocell Clinical Research Private Limited last Annual general meeting of members was held on 31 Dec 2020 as per latest MCA records. was completed.
Emprocell Clinical Research Private Limited has filed its annual Financial statements for the year ended 31 Mar 2020 with Roc Mumbai. was recorded as a recent event.
Progress on Volodymyr Radchenko was appointed as a Director was appointed as a Director on 31 Mar 2014 & has been associated with this company since 11 years 8 months . was documented.
Progress on Vasily Babiy was appointed as a Director was appointed as a Director on 19 Aug 2012 & has been associated with this company since 13 years 3 months . was documented.
Progress on Oleksandr Kukharchuk was appointed as a Alternate Director was appointed as a Alternate Director on 19 Aug 2012 & has been associated with this company since 13 years 3 months . was documented.
The activity Viktor Radchenko was appointed as a Director was appointed as a Director on 10 Jun 2006 & has been associated with this company since 19 years 5 months . was completed.
The CIN of Emprocell Clinical Research Private Limited is U24231MH2006PTC161334.
Emprocell Clinical Research Private Limited is headquartered at C-7/1A Ttc Industrial Area, Midc, Village Pawan, E, Navi Mumbai, Maharashtra, 400705.
Emprocell Clinical Research Private Limited was incorporated on 24 April 2006.
The current directors of Emprocell Clinical Research Private Limited are
The primary industry of Emprocell Clinical Research Private Limited is Professional, Scientific And Technical.
Emprocell Clinical Research Private Limited is unlisted.
The authorized capital of Emprocell Clinical Research Private Limited is ₹5.00 Cr, and the paid-up capital is ₹4.61 Cr.
The compliance status of Emprocell Clinical Research Private Limited is Active Non-Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX